Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta

Gynecologic Oncology

Volumn 75, Issue 2, 1999, Pages 248-253

  Vegh, Gyorgy L ^c   Selcuk Tuncer, Z ^a   Fulop, Vilmos ^c   Genest, David R ^b   Mok, Samuel C ^a   Berkowitz, Ross S ^a  

^a Department of Obstetrics and Gynecology   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

MMP; Placenta; TIMP; Trophoblastic disease

Indexed keywords

COLLAGENASE; GELATINASE A; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CHORIOCARCINOMA; CHORION VILLUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTROPHOBLAST; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNCYTIOTROPHOBLAST; TROPHOBLASTIC DISEASE;

EID: 0344631076     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5564     Document Type: Article

References (29)

1. Lewis J L Jr. Diagnosis and management of gestational trophoblastic disease. Cancer. 71:1993;1639-1647.
2. Berkowitz R S, Goldstein D P. Chorionic tumors. N Engl J Med. 335:1996;1740-1748.
3. Berkowitz R S, Goldstein D P. The Management of Molar Pregnancy and Gestational Trophoblastic Tumors. Knapp R C, Berkowitz R S. Gynecologic Oncology. 1993;328-338 McGraw-Hill, New York.
4. Crescimanno C, Foidart J M, Noel A, Polette M, Maquoi E, Birembaut P, Baramova E, Kaufmann P, Castellucci M. Cloning of choriocarcinoma cells shows that invasion correlates with expression and activation of gelatinase A. Exp Cell Res. 227:1996;240-251.
5. Lala P K, Graham C H. Mechanism of trophoblast invasiveness and their control: the role of proteases and protease inhibitors. Cancer Metast Rev. 9:1994;369-379.
6. Huppertz B, Kerschanska S, Demir A Y, Frank H G, Kaufmann P. Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. Cell Tissue Res. 291:1998;133-148.
7. Bishof P, Haenggli L, Campana A. Gelatinase and oncofetal fibronectin expression is dependent on integrin expression on human cytotrophoblasts. Hum Reprod. 10:1995;734-742.
8. Castellucci M, Theelen T, Pompili E, Fumagalli L, De Renzis G, Muhlhauser J. Immunohistochemical localization of serine-protease inhibitors in the human placenta. Cell Tissue Res. 278:1994;283-289.
9. Leber T, Boyd R, Balkwill F. Tumour Cell-Stromal Cell Interactions: Proteases and Protease Inhibitors. Sharp F, Blackett T, Berek J, Bast R. Ovarian Cancer 5. 1998;121-129 Isis Medical Media Ltd, Oxford.
10. Sato H, Takino T, Okada Y. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature. 370:1994;61-65.
11. Murray G I, Duncan M E, Arbucle E, Melvin W T, Fothergill J E. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut. 43:1998;791-797.
12. Denhardt D T, Feng B, Edwards D R. Tissue inhibitor of metalloproteinases (TIMP, akaEPA): structure, control of expression and biological functions. Pharmacol Ther. 59:1993;329-341.
13. Matrisian L M. The matrix-degrading metalloproteinases. Bioessays. 14:1992;455-462.
14. Chambers A F, Matrisian L M. Changing views of the role of matrix metalloproteinases in metastasis. JNCI. 89:1997;1260-1270.
15. Berkowitz R S, Goldstein D P. Presentation and Management of Molar Pregnancy. Hancock B W, Newlands E S, Berkowitz R S. Gestational Trophoblastic Disease. 1997;127-142 Chapman & Hall, London.
16. Goldstein D P, Zanten-Przybysz I V, Bernstein M R, Berkowitz R S. Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy. J Reprod Med. 43:1998;37-43.
17. Fulop V, Mok S C, Genest D R, Szigetvari I, Cseh I, Berkowitz R S. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med. 43:1998;101-110.
18. Cottam D W, Rees R C. Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis. Intl J Oncol. 2:1993;861-872.
19. Murphy G, Reynolds J J, Hembry R M. Metalloproteinases and cancer invasion and metastasis. Int J Cancer. 44:1989;757-760.
20. Murray G I, Duncan M E, O'Neil P. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 2:1996;461-462.
21. Murray G I, Duncan M E, O'Neil P. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 185:1998;256-261.
22. Montironi R, Fabris G, Lucarini G, Biagini G. Location of 72-kD metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. Path Res Pract. 191:1995;1140-1146.
23. Montironi R, Lucarini G, Castaldini C, Galluzzi C M, Biagini G, Fabris G. Immunohistochemical evaluation of type IV collagenase (72-kD metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res. 16:1996;2057-2062.
24. Tamakoshi K, Kikkawa F, Nawa A, Ishikawa H, Mizuno K, Tamakoshi A, Yamagata S, Suganuma N, Tomoda Y. Characterization of extracellular matrix degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer. 76:1995;2565-2571.
25. Davidson B, Goldberg I, Liokumovich P, Kopolovic J, Gotlieb W H, Lerner-Geva L, Reder I, Ben-Baruch G, Reich R. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 17:1998;295-301.
26. Talvensaari-Mattila A, Apaja-Sarkkinen M, Hoyhtya M, Westerlund A, Puistola U, Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol. 72:1999;306-311.
27. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb W H, Weis B, Ben-Baruch G, Reich R. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix - clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol. 72:1999;380-386.
28. Rasmussen H S, McCann P P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with specifial focus on batimastat and marimastat. Pharmacol Ther. 75:1997;69-75.
29. Wojtowitz-Praga S, Torri J, Johnson M, Steen V, Marchall J, Ness E, Bickson R, Sale M, Rasmussen H S, Chiodo T A, Hawkins M J. Phase I trial Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 16:1998;2150-2156.